Synthesis and biological evaluation of chemokine receptor ligands with 2-benzazepine scaffold

Article abstract of DOI:10.1016/j.ejmech.2017.04.046

Targeting CCR2 and CCR5 receptors is considered as promising concept for the development of novel antiinflammatory drugs. Herein, we present the development of the first probe-dependent positive allosteric modulator (PAM) of CCR5 receptors with a 2-benzazepine scaffold. Compound 14 (2-isobutyl-N-({[N-methyl-N-(tetrahydro-2H-pyran-4-yl)amino]methyl}phenyl)-1-oxo-2,3-dihydro-1H-2-benzazepine-4-carboxamide) activates the CCR5 receptor in a CCL4-dependent manner, but does not compete with [³H]TAK-779 binding at the CCR5. Furthermore, introduction of a p-tolyl moiety at 7-position of the 2-benzazepine scaffold turns the CCR5 PAM 14 into the selective CCR2 receptor antagonist 26b. The structure affinity and activity relationships presented here offer new insights into ligand recognition by CCR2 and CCR5 receptors.

Full text of DOI:10.1016/j.ejmech.2017.04.046

Accepted Manuscript
Synthesis and biological evaluation of chemokine receptor ligands with 2-
benzazepine scaffold
Simone Thum, Artur Kokornaczyk, Tomoaki Seki, Monica De Maria, Natalia V. Ortiz
Zacarias, Henk de Vries, Christina Weiss, Michael Koch, Dirk Schepmann, Masato
Kitamura, Nuska Tschammer, Laura H. Heitman, Anna Junker, Bernhard Wünsch
PII:
S0223-5234(17)30312-4
10.1016/j.ejmech.2017.04.046
EJMECH 9397
DOI:
Reference:
To appear in: European Journal of Medicinal Chemistry
Received Date: 14 March 2017
Revised Date: 14 April 2017
Accepted Date: 19 April 2017
Please cite this article as: S. Thum, A. Kokornaczyk, T. Seki, M. De Maria, N.V. Ortiz Zacarias, H. de
Vries, C. Weiss, M. Koch, D. Schepmann, M. Kitamura, N. Tschammer, L.H. Heitman, A. Junker, B.
Wünsch, Synthesis and biological evaluation of chemokine receptor ligands with 2-benzazepine scaffold,
European Journal of Medicinal Chemistry (2017), doi: 10.1016/j.ejmech.2017.04.046.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT
1
Synthesis and biological evaluation of chemokine receptor ligands with 2-benzazepine scaffold
Simone Thum,a Artur Kokornaczyk,a Tomoaki Seki,b Monica De Maria,c,d Natalia V. Ortiz Zacarias,e
Henk de Vries,e Christina Weiss,f Michael Koch,f Dirk Schepmann,a Masato Kitamura,b Nuska
Tschammer,g Laura H. Heitman,e Anna Junker,a,h Bernhard Wünscha,h*
a
Institut für Pharmazeutische und Medizinische Chemie der Westfälischen Wilhelms-Universität
Münster, Corrensstraße 48, D-48149 Münster, Germany
Tel.: +49-251-8333311; Fax: +49-251-8332144; E-mail: wuensch@uni-muenster.de
b
Graduate School of Pharmaceutical Sciences, Nagoya University Chikusa, Nagoya 464-8602, Japan
c
Department of Chemistry and Pharmacy, Emil Fischer Center, Friedrich Alexander University,
Schuhstraße 19, 91052 Erlangen, Germany.
d
Department of Developmental Biology, Friedrich Alexander University, Staudtstraße 5, 91058
Erlangen, Germany
e
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (LACDR), Leiden
University, P.O. Box 9502, 2300 RA Leiden, the Netherlands
f Bayer AG, Pharmaceuticals, Drug Discovery - Lead Discovery Wuppertal, Aprather Weg 18a,
Gebäude 456, D-42096 Wuppertal, Germany.
g NanoTemper Technologies GmbH, Floessergasse 4, 81369 München
h
Cells-in-Motion Cluster of Excellence (EXC 1003 – CiM), Westfälische Wilhelms-Universität
Münster, Germany

ACCEPTED MANUSCRIPT
2
Abstract
Targeting CCR2 and CCR5 receptors is considered as promising concept for the development of novel
antiinflammatory drugs. Herein, we present the development of the first probe-dependent positive
allosteric modulator (PAM) of CCR5 receptors with a 2-benzazepine scaffold. Compound 14 (2-
isobutyl-N-({[N-methyl-N-(tetrahydro-2H-pyran-4-yl)amino]methyl}phenyl)-1-oxo-2,3-dihydro-1H-2-
benzazepine-4-carboxamide) activates the CCR5 receptor in a CCL4-dependent manner, but does not
compete with [3H]TAK-779 binding at the CCR5. Furthermore, introduction of a p-tolyl moiety at 7-
position of the 2-benzazepine scaffold turns the CCR5 PAM 14 into the selective CCR2 receptor
antagonist 26b. The structure affinity and activity relationships presented here offer new insights into
ligand recognition by CCR2 and CCR5 receptors.
Key words
Chemokine receptors; CCR5; CCR2; positive allosteric modulator, 2-benzazepines; TAK-779, TAK-
652; structure-affinity relationships; structure activity relationships.
1. Introduction
Since the first purification and description of the chemoattractant cytokine secreted platelet factor 4
(PF4/CXCL4) in 19771 more than 50 human chemokines have been discovered.2 Their effects are
mediated by 19 G-protein-coupled chemokine receptors. The chemokine receptors CCR2 and CCR5
share 72% sequence identity (82% identity in their active sites).3 Both receptors play a crucial role in
trafficking of immune cells such as macrophages and monocytes, relevant for the development and
progression of immunologic and cardiovascular diseases.4 The CCR2 receptor is abundantly expressed
on blood monocytes and regulates their migration from the bone marrow into inflamed tissue, whereas
the CCR5 receptor is expressed on macrophages, T-lymphocytes, and natural killer cells..5-7 CCR2 and

ACCEPTED MANUSCRIPT
3
CCR5 receptors are expressed on different cells, but in a complementary manner. Therefore, dual as
well as selective targeting of CCR2 and CCR5 receptors appears to have great potential in the
development of novel concepts for the therapy of inflammatory diseases (e.g. atherosclerosis).5
The benzo[7]annulene TAK-779 (1) represents one of the first potent non-peptide CCR5 receptor
antagonists (IC50 = 1.4 nM, Figure 1). TAK-779 does not only interact with the CCR5 receptor, but also
with the CCR2 receptor, although its CCR2 affinity is about 20-fold lower (IC50 = 27 nM) compared to
its CCR5 affinity.8 However, the quaternary ammonium group of TAK-779 leads to very low oral
bioavailability. Therefore, very recently we have reported a large structure affinity relationship study
with TAK-779 analogs containing a tertiary amine instead of the quaternary ammonium group.
Depending on the substitution pattern, potent CCR2 selective and dual CCR2 and CCR5 targeting
antagonists were found.9-11
Figure 1: Design of 2-benzazepin-1-ones 3 derived from TAK-779 (1) and TAK-652 (2).

ACCEPTED MANUSCRIPT
4
In addition to TAK-779, the benzazocine TAK-652 (2) served as lead compound in this project (Figure
1). TAK-652 shows high and similar affinities towards CCR5 (IC50 = 3.1 nM) and CCR2 receptors (IC50
= 5.9 nM), but does not contain a quaternary ammonium group, which had been replaced by a polar
sulfoxide.12 Structure affinity relationship (SAR) studies performed by Takeda laboratories have shown
that reduction of the ring from a benzazocine to a benzazepine did not result in considerable loss of
CCR5 affinity. The introduction of an isobutyl side chain onto the benzazocine ring increased CCR5
binding affinity.12
Thus, we envisaged to combine the structures of TAK-779 and TAK-652 in 2-benzazepinones 3. The
dihydro-2-benzazepin-1-one system of 3 contains a benzannulated seven-membered ring as TAK-779
and an N-heterocycle bearing an isobutyl moiety as TAK-652. The basicity of the amino group in TAK-
652 (2) is rather low, due to its position at the phenyl ring and due to its conjugation with the amide
group at 5-position (phenylogous / vinylogous urea). In the dihydro-2-benzazepin-1-one system 3 the
basicity of the N-heterocycle is also negligible (lactam). The position of the lipophilic isobutyl moiety
(red) is shifted from 1-position in TAK-652 (2) to 2-position in 3. The selection of substituents X and R
was inspired by the substituents of the lead compounds 1 and 2 and our previous SAR studies.9-11 The
interaction of the final compounds with CCR2 and CCR5 receptors was evaluated in various
biochemical assays.
2. Results and discussion
2.1. Synthesis
The synthesis of the central building block 11 started with a Michael addition of isobutylamine (5) at
methyl acrylate (4) yielding the aminopropanoate 6, which was purified as HCl salt (Scheme 1). Amine
6 was acylated with commercially available 2-(methoxycarbonyl)benzoic acid (monomethyl phthalate,

ACCEPTED MANUSCRIPT
5
7), which was first converted into its acid chloride using SOCl2. Treatment of the resulting diester 8 with
NaH in boiling THF induced the Dieckmann cyclization to produce the cyclic β-ketoester 9. According
to the NMR spectra in CDCl3 solution, 9 exists almost exclusively as enol ester as shown in Scheme 1.
Scheme 1: Synthesis of compounds 14 and 16. Reagents and reaction conditions: (a) 1. NaOCH3,
H3COH, rt, 2 h; 2. HCl/Et2O, 89%. (b) Monomethyl phthalate (7), SOCl2, pyridine; then addition of
6·HCl, pyridine, CH2Cl2, rt, 4 h, 64%. (c) NaH, THF, reflux, 3 h, 58%. (d) NaBH4, H3COH, 0 °C, 1 h,
58%. (e) H3CSO2Cl, NEt3, DBU, CH2Cl2, rt, 12 h, 76%. (f) 5 M NaOH, H3COH, reflux, 40 min, 100%.
(g) NEt3 (2 equiv.), HATU (1.1 equiv.), THF, rt, 12 h, 14: 48%, 16: 8%.

ACCEPTED MANUSCRIPT
6
Reduction of the enol ester 9 with NaBH4 in H3COH afforded two diastereomeric β-hydroxy esters 10.
Since in the next step both diastereomers of 10 form the same α,β-unsaturated ester 11, the
diastereomeric β-hydroxy esters 10 were not separated. Elimination of H2O was performed upon
treatment of β-hydroxy esters 10 with methanesulfonyl chloride in the presence of NEt3. Subsequent
addition of DBU induced the β-elimination of the intermediate methanesulfonate to give the α,β-
unsaturated ester 11 in 76% yield. Saponification of methyl ester 11 with NaOH provided the acid 12 in
almost quantitative yield.
The acid 12 was used to prepare secondary amides 14 and 16, which have similar structures as the lead
compounds 1 and 2. For the amide coupling the uronium salt O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-
tetramethyluronium hexafluorophosphate (HATU) was used. Whereas coupling of acid 12 with the
primary amine 13 provided the secondary amide 14 in 48% yield, the corresponding coupling with
sulfathiazole (15) gave only 8% of secondary amide 16.
In the BRET-based cAMP assay, TAK-779-derived secondary amide 14 showed a CCL4-dependent
positive allosteric modulation (PAM) of CCR5 receptor (see part 3, Biological activity), whereas the
sulfonamide derivative 16 was inactive, indicating the requirement of a basic benzylamine moiety for
CCR5 receptor binding. This promising result stimulated further exploration of the substitution pattern
of compound 14. At first, a bromine atom should be introduced into the benzene moiety of the 2-
benzazepine ring of the key compound 11, since bromoarenes could be used for the introduction of a
broad variety of diverse substituents by Pd-catalyzed cross-coupling reactions. Unfortunately, all
attempts to brominate 11 using Br2 or NBS under different reaction conditions led to loss of the double
bond of the α,β unsaturated ester indicating higher reactivity of the double bond compared to the
benzene ring.

ACCEPTED MANUSCRIPT
7
Therefore, it was planned to change the synthetic strategy and introduce the Br-atom at a very early
stage of the synthesis. For this purpose, phthalic anhydride (17) was treated with an aqueous solution of
NaOH and Br2 which provided 4-bromophthalic acid (18)13 in 95% yield (Scheme 2). Treatment of
diacid 18 with methanol in the presence of TMSCl provided a 1:1 mixture of regioisomeric monomethyl
esters 19a and 19b in 94% yield. The further synthetic route to obtain esters 23 is very similar to the
synthesis of ester 11. Activation of the mono acids 19a,b with SOCl2 and subsequent reaction of the acid
chlorides with aminopropanoate 6 led to the amides 20, which underwent Dieckmann condensation to
afford the enol esters 21a,b. NaBH4 reduction of 21a,b provided the β-hydroxyesters 22a,b, which
reacted with mesyl chloride and DBU to yield the α,β-unsaturated esters 23a,b. In the next step the p-
tolyl moiety of the lead compound TAK-779 (1) should be introduced. Suzuki-Miyaura cross-coupling
of the regioisomeric bromo derivatives 23a,b with 4-methylbenzeneboronic acid and PdCl2(dppf) as
catalyst provided the regioisomeric p-tolyl derivatives 24a,b. Saponification of the esters 24a,b with
NaOH led to acids 25a,b, which were coupled with amine 13 to afford the final amides 26a,b (Scheme
2).

ACCEPTED MANUSCRIPT
8
Scheme 2: Synthesis of 7- and 8-(p-tolyl)-2-benzazepine-4-carboxamides 26a,b. Reagents and reaction
conditions: (a) Br2, NaOH, H2O, reflux, 72 h, 95%. (b) TMSCl, H3COH, rt, 12 h, 94%. (c) 1. SOCl2,
pyridine; 2. 6·HCl, pyridine, CH2Cl2, rt, 4 h, 64%. (d) NaH, THF, reflux, 3 h, 21a: 36%, 21b: 38%. (e)
NaBH4, H3COH, 0 °C, 1 h, 22a: 58%, 22b: 45%. (f) H3CSO2Cl, NEt3, DBU, CH2Cl2, rt, 12 h, 23a: 74%,
23b: 84%. (g) 4-Methylbenzeneboronic acid, PdCl2(dppf) (5 mol%), KOAc, DME, reflux, 12 h, 24a:
50%, 24b: 58%. (h) 5 M NaOH, H3COH, reflux, 30 min, 97%. (i) 13, HATU, NEt3, THF, rt, 12 h, 26a:
39%, 26b: 34%.
The separation of the regioisomers a and b was performed at various stages at the synthesis. Separation
at the very early stage of enol esters 21 and performing the synthesis with pure regioisomers 21a and
21b gave clear spectra of all intermediates. An X-ray crystal structure of the 7-bromo derivative 21b
proved the existence of the β-ketoester in the enol tautomer and the position of the Br-atom.14

ACCEPTED MANUSCRIPT
9
Separation of the intermediate α,β-unsaturated esters 23a and 23b gave higher yields than the early
separation of 21a and 21b. However, separation of the final p-tolyl derivatives 26a and 26b turned out
to be the most efficient strategy, since the corresponding transformations and purifications had to be
performed only once for the mixture of regioisomers, respectively. However, preparative HPLC had to
be used for the separation of 26a and 26b and the NMR spectra of all intermediates showed two sets of
signals.
Scheme 3: Synthesis of NO2 derivatives 29 and acetamide 34a. Reagents and reaction conditions:
(a) HNO3 (100%), H2SO4 (95 – 97%), CH3NO2, rt, 2 h, 83%. (b) 5M NaOH, H3COH, reflux, 97%. (c)
13, HATU, NEt3, THF, rt, 12 h, 29a: 9%, 29c: 14%. (d) Fe, conc. HCl, EtOH, reflux, 2 h, 75%. (e)
Ac2O, NEt3, CH2Cl2, 6 h, rt, 59%. (f) NaOH, H3COH, 10 min, rt. (g) Ac2O, NEt3, CH2Cl2, 6 h, rt, 69%.
(h) 13, HATU, NEt3, THF, rt, 12 h, 47%.
In addition to the p-tolyl moiety, the introduction of electron withdrawing NO2 group was envisaged,
which could be converted into various other functional groups, subsequently. For this purpose, the naked
α,β-unsaturated ester 11 was reacted with HNO3/H2SO4 to obtain a mixture of regioisomeric 8-NO2- and

ACCEPTED MANUSCRIPT
10
6-NO2-2-benzazepines 27a and 27c in the ratio 7:3 in 97% yield (Scheme 3). After chromatographic
separation of the regioisomeric esters 27a and 27c, saponification with NaOH led to the acids 28a and
28c, which were coupled with the amine 13 to afford the final amides 29a and 29c.
The main regioisomer 27a was reduced with Fe in the presence of HCl to provide the primary amine
30a, which was acylated with Ac2O to give the acetamide 31a (Scheme 3). In the next step, the ester 31a
was treated with NaOH. Unexpectedly, not only the ester moiety but also the acetamide group was
hydrolyzed to produce the amino acid 32a. Therefore, the amino moiety was acetylated once more with
Ac2O, before the final HATU-coupling of the acid 33a with amine 13 was performed to produce the
desired acetamide 34a.
Scheme 4: Synthesis of sulfonamide 38a: Reagents and reaction conditions: (a) Fe, conc. HCl, EtOH,
reflux, 2 h, 74%. (b) CH3SO2Cl (1 equiv.), NEt3, CH2Cl2, 3 d, then 4 x 0.3 equiv. CH3SO2Cl and NEt3
every 6 h, rt, 91%. (c) NaOH, H3COH, 20 min, rt, 43%. (d) LiOH (4 equiv.), H3COH, 3 h rt, 1 h 50 °C,
53%. (e) 13, HATU, NEt3, THF, rt, 12 h, 20%.
Reduction of the regioisomers NO2-derivatives 27a,c with Fe and conc. HCl provided a mixture of
regioisomeric primary amines 30a,c, which was treated with methanesulfonyl chloride in the presence of
triethylamine. Although only one equivalent of methanesulfonyl chloride was added, considerable

ACCEPTED MANUSCRIPT
11
amounts of disulfonamides 35a,c were formed. Therefore, an excess of methanesulfonyl chloride was
used to obtain the disulfonamides 35a,c in 91% yield. Subsequent hydrolysis of the disulfonamides
35a,c with NaOH in methanol produced the monosulfonamides 36a,c. Finally, the ester moiety of 36a,c
was hydrolyzed with LiOH. Chromatographic purification of the resulting acids provided the main
regioisomer 37a in 53% yield, which was coupled with the amine 13 to afford the amide 38a in 20%
yield (Scheme 4).
2.2. Biological activity
The interaction of sulfathiazole coupled amide 16 as well as 2-benzazepine-4-carboxamides 14, 26, 29,
34, and 38 bearing different substituents in 8- (a-series), 7- (b-series) and 6-position (c-series) with
CCR2 and CCR5 receptors was tested in various CCR2 and CCR5 assays.
In the first assay, the test compounds competed with the radioligand [3H]INCB3344 for CCR2 receptor
binding on membrane preparations from U2OS cells stably expressing CCR2. With exception of the 7-
p-tolyl derivative 26b, the test compounds did not reduce the specific binding of the radioligand
[3H]INCB3344 to a large extent at a concentration of 1 µM indicating rather low CCR2 affinity (Table
1). Only the 7-p-tolyl derivative 26b displayed a moderate CCR2 affinity with an IC50 value of 387 nM.
In addition to binding, the antagonistic activity of the test compounds at the CCR2 receptor was
determined in a Ca2+ flux assay employing the Chem-1 cell line stably transfected with the human
CCR2b receptor. Influx of Ca2+ ions was induced by recombinant human CCL2 (MCP-1). The inhibition
of this Ca2+ influx by the test compounds was recorded. Table 1 shows that only the p-tolyl derivatives
26 were able to inhibit the Ca2+ influx. Whereas the 8-p-tolyl derivative 26a revealed only very low
inhibition, a significant inhibition was observed for the regioisomer 26b. This result is explained by the

ACCEPTED MANUSCRIPT
12
structural relationship of 26b and the lead compound TAK-779. However, the IC50 value of 140 nM is
considerably higher than the IC50 value of TAK-779. The inhibition of the Ca2+ flux induced by the 7-p-
tolyl derivative 26b correlates nicely with its moderate CCR2 binding affinity.
Table 1: Receptor affinities and activities at CCR2 and CCR5 receptors.
CCR2
[3H]INCB3344
CCR5
[3H]TAK-779
cAMP-BRET
(CCL4)
Ca2+ flux
displacement
Compd.
R
displacement
IC50 (nM)[b]
IC50 (nM)[a]
IC50 [nM][c]
EC50 (nM)[d]
H
H
18%
18%
0%
n.d.
n.d.
3000
140
n.d.
n.d.
n.d.
n.d.
0.95
0%
0%
0%
0%
0%
0%
0%
0%
2
2470
> 10
> 10
> 10
> 10
> 10
> 10
> 10
7
14
16
8-p-tolyl
7-p-tolyl
8-NO2
6-NO2
8-NHAc
8-NHSO2CH3
-
26a
387
9%
26b
29a
6%
29c
15%
18%
50
34a
38a
TAK-779
[%] inhibition at a test compound concentration of 1 µM (n = 3). n.d. not determined.
[a]
Displacement of the radioligand [3H]INCB3344 at a concentration of 1 µM of the test
compound (n = 3).
[b]
[c]
Inhibition of Ca2+ mobilization after activation by 5 nM MCP-1 (n = 3).
Displacement of the radioligand [3H]TAK-779 at a concentration of 1 µM of the test

ACCEPTED MANUSCRIPT
13
compound (n = 3).
Stimulation of cAMP production after inhibition with 0.2 nM CCL4 (n = 3).
[d]
For investigation of the interaction of the test compounds with CCR5 receptors, a binding assay was
performed at first. In this assay the radioligand [3H]TAK-779 was used as competitor and commercially
available membrane preparations containing high amounts of CCR5 receptors were employed as source
of receptors. At a concentration of 1 µM the test compounds could not displace the specific radioligand
binding (Table 1). In particular, the low CCR5 interaction of the p-tolyl derivative 26b was unexpected,
as this compound is structurally very similar to the lead compound TAK-779. To address the surprising
lack of CCR5 affinity of compound 26b, the central core structures of 26b (B) and TAK-779 (A) were
compared via flexible alignment. In Figure 2, part I the superposition of the core structures demonstrates
different angles within the 7-membered rings of TAK-779 (1) and 2-benzazepinone 26b. The different
arrangement of the 7-membered ring of 26b compared to TAK-779 might explain the reduced or
eliminated CCR5 affinity of 26b. Obviously, the CCR5 receptor does not tolerate the introduction of the
N-isobutyl substituted amide moiety within the seven-membered part of the ring system. On the other
hand, an alignment of the core structures of 26b (B) and TAK-652 (C) (Figure 2, part II) reveals a very
similar positioning of the isobutyl chain that might explain the moderate CCR2 binding affinity and
activity.
I
II

ACCEPTED MANUSCRIPT
14
Figure 2: I) Alignment of central core structures of TAK-779 (A, blue) with 7-p-tolyl derivative 26b (B,
pink). II) Alignment of central core structures of TAK-652 (C, orange) with 7-p-tolyl derivative 26b (B,
pink).
To assess the effect of compounds on the CCL4 or CCL5-induced Gi protein-dependent signaling of
CCR5, we monitored the changes in cAMP levels by use of the bioluminescence resonance energy
transfer- (BRET-) based cAMP sensor CAMYEL. This biosensor is comprised of a catalytically inactive
Epac1 that is fused to Citrine at its N-terminus and to Renilla reniformis luciferase (Rluc) at the C-
terminus.15 For these experiments, HEK293T cells were transiently transfected with the human CCR5
receptor and the CAMYEL biosensor. The accumulation of cAMP was induced by forskolin. TAK-779
(1) was used as reference inhibitor of CCL4 and CCL5 action.

ACCEPTED MANUSCRIPT
15
175
150
125
100
75
14
1 nM CCL4, 14
1 nM CCL4, TAK-779
50
25
0
-12 -11 -10 -9 -8 -7 -6 -5 -4
Concentration (log[M])
Figure 3: The BRET-based cAMP assay for compounds 14 and TAK-779 (1) with CCL4 at the CCR5
receptor.
In the cAMP assay only the unsubstituted 2-benzazepinone 14 displayed remarkable biological effects.
This compound showed clear probe-dependence at the CCR5 receptor. Although that compound 14
itself had no intrinsic agonist activity (Figure 3), it behaved as positive allosteric modulator (PAM)
when CCL4 was used to activate the CCR5 receptor (IC50 = 2.47 μM, Table 1, Figure 3). At the same
time, the compound 14 was fully inactive in the presence of CCL5. This CCL4-dependence indicates a
slightly different CCR5 receptor binding pocket for compound 26b compared to TAK-779, since TAK-
779 displays a negative allosteric modulation with both chemokines CCL4 and CCL5. Of note, probe-
dependent negative allosteric modulators (NAM) of CXCR3 receptors were recently reported.16,17
Probe-dependent allosteric modulation provides a promising strategy for fine tuning of the chemokine
response and corresponding ligands are therefore of great interest for drug development in the
chemokine receptor field. If we consider that 14 binds to a different subpocket than TAK-779, the lack
of CCR5 affinity of 14 in a radioligand binding assay is not surprising, as it would not compete with

ACCEPTED MANUSCRIPT
16
[3H]TAK-779. In the benzene ring of the sulfathiazole-derived amide 16 further substituents are also
missing. However, 16 does not induce similar effects as 14, which is probably due to the lacking basic
amino moiety.
3. Conclusion
The introduction of the p-tolyl group at 7-position of the 2-benzazepine scaffold seems to be crucial for
CCR2 receptor interactions. In the CCR2 binding assay and the Ca2+ flux assay, the 7-p-tolyl derivative
26b displayed moderate affinity (IC50 = 387 nM) and activity (IC50 = 140 nM). Obviously the CCR2
receptor is able to accommodate at the different structure of the 2-benzazepinone 26b compared to the
structures of the lead compounds TAK-779 and TAK-652. Despite the different conformations of the
scaffolds, the isobutyl moieties of TAK-652 and 26b adopt similar orientations, which might explain the
moderate interactions of 26b with the CCR2 receptor. The corresponding 8-p-tolyl regioisomer 26a was
approx. 20-fold less potent in both assays, other substituents at the 2-benzazepine framework were not
tolerated by the CCR2 receptor.
The synthesized 2-benzazepinones did not show any affinity towards the CCR5 receptor in the
[3H]TAK-779 competition assay. Despite the absence of TAK-779 displacement at CCR5 receptors, the
naked 2-benzazepinone 14 led to an increased production of cAMP after stimulation of the CCR5
receptor with CCL4. This probe-dependent positive allosteric modulation of the CCR5 receptor, which
was not observed after stimulation with CCL5, was unexpected.

ACCEPTED MANUSCRIPT
17
4. Experimental Part
4.1. General
Unless otherwise noted, moisture sensitive reactions were conducted under dry nitrogen. THF was dried
with sodium/benzophenone, CH2Cl2 with calcium hydride and both were freshly distilled before use.
Thin layer chromatography (tlc): Silica gel 60 F254 plates (Merck). Flash chromatography (fc): Silica gel
60, 40–64 µm (Merck); parentheses include: diameter of the column, length of column, fraction size,
eluent, Rf value. Melting point: melting point system MP50 (Mettler Toledo), uncorrected. IR: IR
1
13
spectrophotometer 480Plus FT-ATR-IR (Jasco). H NMR (400 MHz), C NMR (100 MHz): Mercury
plus 400 spectrometer (Varian); δ in ppm related to tetramethylsilane; coupling constants are given with
0.5 Hz resolution. MS: APCI = atmospheric pressure chemical ionization: MicroTOFQII (Bruker
Daltonics), ESI = electro spray ionization: MicroTof (Bruker Daltonics, Bremen), calibration with
sodium formate clusters before measurement. Deviations of the found exact masses from the calculated
exact masses were 5 mDa or less, unless otherwise stated. The data were analyzed with DataAnalysis
(Bruker).
4.2. HPLC methods
4.2.1. Method 1: Purity of compounds
Merck Hitachi equipment; UV detector: L-7400; autosampler: L-7200; pump: L-7100; degasser:
L-7614; Method A: column: LiChrospher® 60 RP-select B (5 µm), 250-4 mm cartridge; flow rate: 1.00
mL/min; injection volume: 5.0 µL; detection λ = 210 nm; solvents: A: water with 0.05% (v/v)
trifluoroacetic acid; B: acetonitrile with 0.05% (v/v) trifluoroacetic acid: gradient elution: (A %): 0-4
min: 90% , 4-29 min: gradient from 90% to 0%, 29-31 min: 0%, 31-31.5 min: gradient from 0% to 90%,
31.5-40 min: 90%.

ACCEPTED MANUSCRIPT
18
4.2.2. Method 2: Preparative HPLC
Merck Hitachi equipment; UV detector: L-7400; autosampler: L-7200; pump: L-7100; interface: D-
7000; data acquisition: HSM Software (LaChrom, Merck-Hitachi); solvent: acetonitrile : H2O 70:30;
column: Phenomenex® Gemini 5 µm C18 110A, 250 – 21.2 mm; flow rate: 10.00 mL/min; injection
volume 500.0 µL; detection: wavelength: 254 nm, stop time: 60.0 min.
4.3. Synthetic procedures
4.3.1. Methyl 3-(isobutylamino)propanoate (6•HCl)
Methyl 4-acrylate (9.81 g, 114 mmol, 15.0 mL) was added slowly to a vigorously stirred mixture of
isobutylamine (10 g, 137 mmol, 13.6 mL) and sodium methanolate (123 mg, 2.28 mmol) in methanol
(70 mL). The mixture was stirred for 2 h at rt, concentrated in vacuo and the residue was purified by fc
(Ø = 4 cm, h = 16 cm, cyclohexane / ethyl acetate = 1 : 2 + 1% triethylamine, Rf = 0.71) to give a
colorless oil. The oil was dissolved in Et2O and 2 M HCl in Et2O was added to the solution. A colorless
precipitate was formed, which was separated by filtration with Et2O to give 6 as a HCl-salt. Colorless
solid, mp 187 °C, yield 23.8 g (89%). C8H18ClNO2, Mr = 195.7. Exact MS (APCI): m/z = 160.1380
1
(calcd. 160.1332 for C8H18NO2 [MH+]). H NMR (DMSO-d6): δ [ppm] = 0.94 (d, J = 6.7 Hz, 6H,
NCH2CH(CH3)2), 1.90 - 2.05 (m, 1H, NCH2CH(CH3)2), 2.75 (d, J = 7.1 Hz, 2H, NCH2CH(CH3)2), 2.83
(t, J = 7.5 Hz, 2H, CH2CH2CO2CH3), 3.12 (t, J = 7.4 Hz, 2H, CH2CH2CO2CH3), 3.64 (s, 3H, CO2CH3),
8.88 (s, 2H, NH2). 13C NMR (DMSO-d6): δ [ppm] = 19.9 (2C, NCH2CH(CH3)2), 25.2 (1C,
NCH2CH(CH3)2), 29.8 (1C, CH2CH2CO2CH3), 42.6 (1C, CH2CH2CO2CH3), 51.7 (1C, CO2CH3), 53.7
(1C, NCH2CH(CH3)2), 170.4 (1C, CO2CH3). IR (neat): ν [cm-1] = 1736 (C=O), 1593 (C-N).
4.3.2. Methyl 2-{N-isobutyl-N-[2-(methoxycarbonyl)ethyl]-carbamoyl}-benzoate (8)
Monomethyl phthalate (7, 6.24 g, 34.6 mmol) was added to a vigorously stirred solution of SOCl2 (6.18

ACCEPTED MANUSCRIPT
19
g, 52 mmol, 3.77 mL) in CH2Cl2 (20 mL) and the mixture was heated to reflux for 1.5 h. The reflux
condenser was replaced by a Liebig micro distillation apparatus to remove CH2Cl2 and SOCl2. The
residue was dissolved in CH2Cl2 (20 mL). Then pyridine (8.21 g, 104 mmol, 8.4 mL, 3 equiv.) and
6•HCl (8.13 g, 41.5 mmol, 1.2 equiv.) were added under ice cooling. After 4 h, the mixture was
concentrated in vacuo, the residue was suspended in sat. NaHCO3 and the mixture was extracted with
CH2Cl2 (3 x 50 mL). The combined organic layers were dried (Na2SO4), concentrated in vacuo and the
residue was purified by fc (Ø = 8 cm, h = 16 cm, cyclohexane / ethyl acetate = 2 : 1, Rf = 0.45) to give 8
as a colorless solid, mp 62 °C, yield 7.12 g (64%). C17H23NO5, Mr = 321.4. Exact MS (APCI): m/z =
322.1659 (calcd. 322.1649 for C17H24NO5 [MH+]). 1H NMR (CDCl3): δ [ppm] = 0.76 (d, J = 6.7 Hz, 6H,
NCH2CH(CH3)2), 1.81 – 1.92 (m, 1H, NCH2CH(CH3)2), 2.79 – 2.91 (m, 4H, CH2CH2CO2CH3), 3.72 (s,
3H, CH2CH2CO2CH3), 3.73 – 3.86 (m, 2H, NCH2CH(CH3)2), 3.86 (s, 3H, ArCO2CH3), 7.28 (dd, J =
7.9/1.0 Hz, 1H, Ar-H), 7.40 – 7.45 (m, 1H, Ar-H), 7.53 – 7.56 (m, 1H, Ar-H), 7.97 – 8.05 (m, 1H, Ar-
H). 13C NMR (CDCl3): δ [ppm] = 20.1 (2C, NCH2CH(CH3)2), 27.1 (1C, NCH2CH(CH3)2), 31.4 (1C,
CH2CH2CO2CH3), 41.2 (1C, NCH2CH(CH3)2), 51.7 (1C, CH2CH2CO2CH3), 52.3 (1C, ArCO2CH3), 56.2
(1C, CH2CH2CO2CH3), 127.7 (1C, Ar-C), 128.5 (1C, Ar-C), 128.7 (1C, Ar-C), 130.4 (1C, Ar-C), 132.6
(1C, Ar-C), 132.7 (1C, Ar-C), 165.8 (1C, ArCO2CH3), 171.4 (1C, CONR2), 172.8 (1C, CO2CH3). IR
(neat): ν [cm-1] = 1725 (C=O), 1625 (NC=O).
4.3.3. Methyl 2-isobutyl-5-hydroxy-1-oxo-2,3-dihydro-1H-2-benzazepine-4-carboxylate (9)
Under ice cooling a dispersion of NaH (60% w/w in mineral oil 540 mg, 13.5 mmol) was added slowly
to a solution of the amide 8 (1.41 g, 4.5 mmol) in THF (20 mL) and left to stir for 0.5 h, then mixture
was heated to reflux for 1.5 h. After cooling to rt the mixture was concentrated in vacuo and the residue
was suspended in 1 M HCl. The aqueous layer was extracted with CH2Cl2 (3 x 50 mL). The combined
organic layers were dried (Na2SO4), concentrated in vacuo and the residue was purified by automatic fc

ACCEPTED MANUSCRIPT
20
(Biotage®, Cartridge SNAP 100 g, cyclohexane / ethyl acetate, Rf = 0.35 (cyclohexane / ethyl acetate = 2
: 1)) to give the 2-benzazepine 9 as a pale yellow solid, mp 84 °C, yield 750 mg (58%). C16H19NO4,
1
Mr = 289.3. Exact MS (APCI): m/z = 290.1387 (calcd. 290.1392 for C16H20NO4 [MH+]). H NMR
(CDCl3): δ [ppm] = 0.95 (d, J = 6.7 Hz, 6H, NCH2CH(CH3)2), 2.00 – 2.13 (m, 1H, NCH2CH(CH3)2),
3.23 - 3.38 (m, 1H, NCH2CH(CH3)2), 3.45 - 3.61 (m, 1H, NCH2CH(CH3)2), 3.68 - 3.82 (m, 1H, 3-CH2),
3.90 (s, 3H, CO2CH3), 4.01 - 4.17 (m, 1H, 3-CH2), 7.53 - 7.61 (m, 2H, Ar-H), 7.84 - 7.90 (m, 1H, Ar-H),
7.98 - 8.03 (m, 1H, Ar-H), 12.56 (s, 1H, OH). 13C NMR (CDCl3): δ [ppm] = 20.3 (2C, NCH2CH(CH3)2),
27.7 (1C, NCH2CH(CH3)2), 43.6 (1C, C-3), 52.4 (1C, CO2CH3), 55.8 (1C, NCH2CH(CH3)2), 102.3 (1C,
C-4), 127 (1C, Ar-C), 130.6 (1C, Ar-C), 130.9 (1C, Ar-C), 131.2 (1C, Ar-C), 131.3 (1C, Ar-C), 136.3
(1C, Ar-C), 167.8 (1C, CONR2), 170.4 (1C, CO2CH3), 171.2 (1C, C-5). IR (neat): ν [cm-1] = 1728
(C=O), 1632 (C=O), 1611 (NC=O).
4.3.4. Methyl 2-isobutyl-5-hydroxy-1-oxo-2,3,4,5-tetrahydro-1H-2-benzazepine-4-carboxylate (10)
NaBH4 (523 mg, 13.8 mmol) was added slowly to a solution of the enol ester 9 (2.0 g, 6.91 mmol) in
abs. H3COH (50 mL) under ice cooling. After 1 h, 1 M HCl (50 mL) was added and the mixture was
extracted with CH2Cl2 (3 x 50 mL). The combined organic layers were dried (Na2SO4), concentrated in
vacuo and the residue was purified by fc (Ø = 3 cm, h = 16 cm, cyclohexane / ethyl acetate = 4 : 1, Rf =
0.18) to give 10 as a colorless solid, mp 154 °C, yield 1.16 g (58%). C16H21NO4, Mr = 291.4. Exact MS
(APCI): m/z = 292.1590 (calcd. 292.1543 for C16H22NO4 [MH+]). 1H NMR (CDCl3): δ [ppm] = 0.92 (d,
J = 6.7 Hz, 6H, NCH2CH(CH3)2), 1.98 – 2.06 (m, 1H, NCH2CH(CH3)2), 3.19 – 3.36 (m, 5H,
NCH2CH(CH3)2, 3-CH2, 4-CH), 3.68 (s, 3H, CO2CH3), 4.60 (d, J = 6.7 Hz, 1H, 5-CH), 7.30 – 7.40 (m,
1H, Ar-H), 7.41 – 7.48 (m, 2H, Ar-H), 7.63 (d, J = 7.3 Hz, 1H, Ar-H). A signal for OH proton is not
seen in the spectrum. 13C NMR (CDCl3): δ [ppm] = 20.5 (2C, NCH2CH(CH3)2), 27.8 (1C,
NCH2CH(CH3)2), 48.1 (1C, NCH2CHCO2CH3), 51.6 (1C, C-3), 52.1 (1C, CO2CH3), 55.1 (1C, C-4),

ACCEPTED MANUSCRIPT
21
70.2 (1C, C-5), 125.1 (1C, Ar-C), 128.2 (1C, Ar-C), 128.5 (1C, Ar-C), 130.9 (1C, Ar-C), 133.2 (1C, Ar-
C), 138.1 (1C, Ar-C), 171.1 (1C, C-1), 171.5 (1C, CO2CH3). IR (neat): ν [cm-1] = 3221 (-OH), 1725
(C=O), 1620 (NC=O).
4.3.5. Methyl 2-isobutyl-1-oxo-2,3-dihydro-1H-2-benzazepine-4-carboxylate (11)
Under ice cooling CH3SO2Cl (1117 mg, 9.75 mmol) was added to a solution of β-hydroxy ester 10
(943.5 mg, 3.25 mmol) and triethylamine (986 mg, 9.75 mmol) in CH2Cl2 (20 mL). The reaction mixture
was stirred overnight at rt. Then DBU (2.47 g, 16.3 mmol) was added under ice cooling. The reaction
mixture was stirred for 1 h at rt. Then 1 M HCl was added and the mixture was extracted with CH2Cl2 (3
x 50 mL). The combined organic layers were dried (Na2SO4), concentrated in vacuo and the residue was
purified by fc (Ø = 3 cm, h = 16 cm, cyclohexane / ethyl acetate = 4 : 1, Rf = 0.6) to give 11 as a
colorless solid, mp 69 °C, yield 679 mg (76%). C16H20NO3, Mr = 273.3. Exact MS (APCI): m/z =
274.1500 (calcd. 274.1432 for C16H21NO3 [MH+]). 1H NMR (CDCl3): δ [ppm] = 0.93 (d, J = 6.7 Hz, 6H,
NCH2CH(CH3)2), 2.01 – 2.13 (m, 1H, NCH2CH(CH3)2), 3.44 (d, J = 7.6 Hz, 2H, NCH2CH(CH3)2), 3.88
(s, 3H, CO2CH3), 3.97 (s, 2H, 3-CH2), 7.34 (dd, J = 5.9/3.7 Hz, 1H, Ar-H), 7.50 (dd, J = 6.0/3.7 Hz, 2H,
Ar-H), 7.82 (s, 1H, 5-CH), 8.09 (dd, J = 5.8/3.5 Hz, 1H, Ar-H). 13C NMR (CDCl3): δ [ppm] = 20.2 (2C,
NCH2CH(CH3)2), 27.7 (1C, NCH2CH(CH3)2), 44.4 (1C, C-3), 52.6 (1C, NCH2CH(CH3)2), 56.3 (1C,
CO2CH3), 129.7 (1C, Ar-C), 129.9 (1C, Ar-C), 130.5 (1C, Ar-C), 131.8 (1C, Ar-C), 132.9 (1C, Ar-C),
133.2 (1C, Ar-C), 136.8 (1C, C-4), 141.7 (1C, C-5), 166.1 (1C, CO2CH3), 168.1 (1C, C-1). IR (neat): ν
[cm-1] = 2924 (C-Haliph.), 1725 (C=O), 1597 (C=C).
4.3.6. 2-Isobutyl-1-oxo-2,3-dihydro-1H-2-benzazepine-4-carboxylic acid (12)
The ester 11 (120 mg, 0.44 mmol) was dissolved in H3COH (10 mL) and 5 M NaOH (10 mL) was
added. The mixture was heated to reflux for 40 min. After cooling down to 0 °C, the mixture was

ACCEPTED MANUSCRIPT
22
acidified with conc. HCl (2.5 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic
layers were dried (Na2SO4) and concentrated in vacuo to give the acid 12. Colorless solid, mp 192 °C,
yield 114 mg (100%). C15H17NO3, Mr = 259.3. Rf = 0.12 (cyclohexane / ethyl acetate = 2 : 1). Exact MS
1
(APCI): m/z = 260.1285 (calcd. 260.1281, for C15H18NO3 [MH+]). H NMR (methanol-d4): δ [ppm] =
0.94 (d, J = 6.7 Hz, 6H, NCH2CH(CH3)2), 2.05 - 2.18 (m, 1H, NCH2CH(CH3)2), 3.46 (d, J = 7.6 Hz, 2H,
NCH2CH(CH3)2), 4.01 (s, 2H, 3-CH2), 7.50 (dd, J = 7./1.5 Hz, 1H, Ar-H), 7.53 - 7.63 (m, 2H, Ar-H),
7.91 (s, 1H, 5-H), 7.99 (dd, J = 7.7/1.6 Hz, 1H, Ar-H). A signal for COOH proton is not seen in the
spectrum. 13C NMR (methanol-d4): δ [ppm] = 20.4 (2C, N-CH2-CH-(CH3)2), 28.8 (1C, N-CH2-CH-
(CH3)2), 45.4 (1C, C-3), 57.2 (1C, N-CH2-CH-(CH3)2), 130.7 (1C, Ar-C), 131.1 (1C, Ar-C), 132.0 (1C,
Ar-C), 132.1 (1C, Ar-C), 135.0 (1C, C-4), 135.30 (1C, Ar-C), 137.11 (1C, Ar-C), 142.00 (1C, C-5),
168.2 (1C, CO2CH3), 170.2 (1C, C-1). IR (neat): ν [cm-1] = 2937 (C-Haliph.), 1715 (C=O), 1600 (C=C).
HPLC (method 1): tR = 17.21 min, purity 98.8%.
4.3.7.
2-Isobutyl-N-({[N-methyl-N-(tetrahydro-2H-pyran-4-yl)amino]methyl}phenyl)-1-oxo-2,3-
dihydro-1H-2-benzazepine-4-carboxamide (14)
Amine 13 (113 mg, 0.44 mmol) was added to a vigorously stirred mixture of acid 12 (113.8 mg, 0.44
mmol), NEt3 (89.1 mg, 0.88 mmol) and HATU (182.5 mg, 0.48 mmol) in abs. THF (5 mL). The mixture
was stirred overnight at rt. Then the mixture was concentrated in vacuo. Saturated NaHCO3-solution (20
mL) was added to the residue and the mixture was extracted with CH2Cl2 (3 x 20 mL). The combined
organic layers were concentrated in vacuo to give a yellow solid, which was purified by fc (Ø = 1.5 cm,
h = 20 cm, CH2Cl2 : H3COH = 9 : 1 + 1% NH3, V = 30 mL, Rf = 0.66) and then by automatic fc
(Biotage®, SNAP Cartridge KP-C18-HS 30 g, water/acetonitrile) to give 14. Colorless solid, yield 97 mg
(48%). C28H35N3O3, Mr = 461.6. Exact MS (APCI): m/z = 462.2709 (calcd. 462.2678 for C28H36N3O3
[MH+]). 1H NMR (CDCl3): δ [ppm] = 0.84 (d, J = 6.6 Hz, 6H, NCH2CH(CH3)2), 1.64 – 1.77 (m, 2H, 3-

ACCEPTED MANUSCRIPT
23
CHpyran, 5-CHpyran), 1.77 – 1.86 (m, 2H, 3-CHpyran, 5-CHpyran), 1.91 – 2.04 (m, 1H, NCH2CH(CH3)2),
2.26 (s, 3H, CH3), 2.70 – 2.83 (m, 1H, 4-CHpyran), 3.34 (d, J = 6.8 Hz, 2H, NCH2CH(CH3)2), 3.39 (d, J =
11.4 Hz, 2H, 2-CHpyran, 6-CHpyran), 3.64 (s, 2H, CH2N), 3.91 (s, 2H, CH2NCO), 4.04 (dd, J = 11.2/3.3
Hz, 2H, 2-CHpyran, 6-CHpyran), 6.88 (d, J = 7.1 Hz, 1H, 6-CH), 7.13 (s, 1H, 5-CH), 7.32 (t, J = 8.3 Hz,
3H, 3-CHaniline, 5-CHaniline, 7-CH), 7.41 (t, J = 7.5 Hz, 1H, 8-CH), 7.76 (d, J = 8.4 Hz, 2H, 2-CHaniline, 6-
13
CHaniline), 7.98 (d, J = 7.8 Hz, 1H, 9-CH), 9.22 (s, 1H, NH). C NMR (CDCl3): δ [ppm] = 20.1 (2C,
NCH2CH(CH3)2), 27.7 (1C, NCH2CH(CH3)2), 29.1 (2C, 3-Cpyran, 5-Cpyran), 37.4 (1C, CH3), 44.6 (1C, 3-
C), 56.2 (1C, NCH2CH(CH3)2), 57.4 (1C, CH2N), 59.9 (1C, 4-Cpyran), 67.6 (2C, 2-Cpyran, 6-Cpyran), 120.3
(2C, 2-Caniline, 6-Caniline), 129.0 (1C, 8-C), 129.4 (1C, 6-C), 129.7 (2C, 3-Caniline, 5-Caniline), 130.7 (1C, C-
8), 130.7 (1C, C-9a), 130.9 (1C, C-9), 135.1 (1C, C-7), 134.4 (1C, C-4aniline), 135.7 (1C, C-5a), 137.8
(1C, C-1aniline), 164.9 (1C, CONH), 168.6 (1C, C-1). The signal for C-4 is not seen in the spectrum. IR
(neat): ν [cm-1] = 3300 (NH), 2939 (CHaliph.), 1650 (C=O), 1022 (C-O). HPLC (method 1): tR = 20.62
min, purity 98.4%.
4,3,8, 2-Isobutyl-1-oxo-N-{4-[N-(thiazol-2-yl)sulfoamoyl]phenyl}-2,3-dihydro-1H-2-benzazepine-4-
carboxamide (16)
Sulfathiazole (15, 47 mg, 0.19 mmol, 1 equiv.) was added to a vigorously stirred mixture of 12 (48 mg,
0.19 mmol, 1 equiv.), NEt3 (51 µL, 38 mg, 0.37 mmol, 2 equiv.) and HATU (77 mg, 0.20 mmol,
1.1 equiv.) in abs. THF (3 mL). The mixture was stirred overnight at rt. The solvent was removed in
vacuo and a saturated solution of NaHCO3 (10 mL) was added to the residue. The mixture was extracted
with CH2Cl2 (2 x 10 mL) and ethyl acetate (2 x 10 mL). The combined organic layers were dried
(Na2SO4) and concentrated in vacuo to give the crude product as yellow oil, which was purified by fc
(Ø = 2 cm, h = 16 cm, CH2Cl2 : H3COH = 97 : 3 + 1% NH3, V = 10 mL, Rf = 0.34 (CH2Cl2 :
H3COH = 95 : 5 + 1% NH3)). Colorless oil, yield 7 mg (8%). C24H24N4O4S2, Mr = 496.6. Exact mass

ACCEPTED MANUSCRIPT
24
1
(APCI): m/z = 497.1296 (calcd. 497.1312 for C24H25N4O4S2 [MH+]). H NMR (DMSO-d6): δ [ppm] =
0.85 (d, J = 6.7 Hz, 6H, NCH2CH(CH3)2), 1.90 – 1.96 (m, 1H, NCH2CH(CH3)2), 3.36 (d, J = 7.5 Hz,
2H, NCH2CH(CH3)2), 3.93 (s, 2H, 3-CH2), 6.83 (d, J = 4.6 Hz, 1H, 5-CHthiazole), 7.26 (d, J = 4.6 Hz, 1H,
4-CHthiazole), 7.55 (m, 2H, 6-CH, 8-CH), 7.62 (td, J = 7.7/1.4 Hz, 1H, 7-CH), 7.77 (s, 1H, 5-CH), 7.79 (d,
J = 8.8 Hz, 2H, 2-CHphenyl, 6-CHphenyl), 7.88 (d, J = 8.8 Hz, 2H, 3-CHphenyl, 5-CHphenyl), 7.93 (m, 1H, 9-
CH), 10.55 (s, 1H, NH), 12.70 (s, 1H, SO2NH). 13C NMR (DMSO-d6): δ [ppm] = 19.9 (2C,
NCH2CH(CH3)2), 27.2 (1C, NCH2CH(CH3)2), 44.1 (1C, C-3), 55.0 (1C, NCH2CH(CH3)2), 108.1 (1C, C-
5
thiazole), 119.6 (2C, C-2phenyl, C-6phenyl), 124.4 (1C, C-4thiazole), 126.8 (2C, C-3phenyl, C-5phenyl), 129.1 (1C,
C-8), 129.6 (1C, C-6), 130.5 (1C, C-7), 131.0 (1C, C-9), 133.1 (1C, C-5a), 135.9 (1C, C-9a), 136.2 (1C,
C-5), 136.8 (1C, C-4phenyl), 137.0 (1C, C-4), 142.2 (1C, C-1phenyl), 165.0 (1C, CONH), 167.0 (1C, C-1),
168.7 (1C, C-2thiazole). IR (neat): ν [cm-1] = 3433 (CONH), 1053 (SO2), 1662 (C=O). HPLC (method 1):
tR = 18.68 min, purity 96.8%.
4.3.9. Methyl 2-isobutyl-1-oxo-8-(p-tolyl)-2,3-dihydro-1H-2-benzazepine-4-carboxylate (24a)
Under a permanent flow of N2, ester 23a (160 mg, 0.45 mmol), PdCl2(dppf) (22 mg, 5 mol %), KOAc
(104 mg, 1 mmol) and 4-methylbenzeneboronic acid (79 mg, 0.5 mmol) were suspended in dry
dimethoxyethane (10 mL). The Schlenk tube was sealed and heated to 100 °C for 12 h. After cooling
down to rt, the mixture was filtered through a short silica pad (ethyl acetate). The filtrate was
concentrated in vacuo to give the crude product as a brown oil, which was purified by automatic fc
(Biotage®, SNAP 50 g, cyclohexane / ethyl acetate) to give 24a. Colorless solid, mp 124 °C, yield 82 mg
(50%). C23H25NO3, Mr = 363.5. 1H NMR (CDCl3): δ [ppm] = 0.92 (d, J = 6.7 Hz, 6H, NCH2CH(CH3)2),
2.08 – 2.17 (m, 1H, NCH2CH(CH3)2), 2.40 (s, 3H, CH3), 3.51 (d, J = 7.6 Hz, 2H, NCH2CH(CH3)2), 3.95
(s, 3H, CO2CH3), 4.14 (s, 2H, 3-CH2), 7.28 – 7.36 (m, 2H, 3-CHtolyl, 5-CHtolyl), 7.47 – 7.65 (m, 3H, 2-
CHtolyl, 6-CHtolyl), 7.64 (dd, J = 8.2/2.0 Hz, 1H, 7-CH), 7.71 (dd, J = 8.2/2.1 Hz, 1H, 6-CH), 7.89 (s, 1H,

ACCEPTED MANUSCRIPT
25
13
5-CH), 8.20 (s, 1H, 9-CH). C NMR (CDCl3): δ [ppm] = 20.2 (2C, NCH2CH(CH3)2), 21.3 (1C, CH3),
27.8 (1C, NCH2CH(CH3)2), 44.5 (1C, C-3), 52.6 (1C, CO2CH3), 56.4 (1C, NCH2CH(CH3)2), 124.3 (1C,
C-7), 127.1 (2C, C-2tolyl, C-6tolyl), 128.1 (1C, C-4), 130.3 (2C, C-3tolyl, C-5tolyl), 132.5 (1C, C-9), 132.9
(1C, C-9a), 134.6 (1C, C-4tolyl), 138.0 (1C, C-5a), 138.8 (1C, C-1tolyl), 141.9 (1C, C-6), 149.2 (1C, C-8),
168.1 (1C, CO2CH3), 170.0 (1C, C-1). IR (neat): ν [cm-1] = 2937 (C-Haliph.), 1728 (C=Oamide), 1600
(C=C).
4.3.10. Methyl 2-isobutyl-1-oxo-7-(p-tolyl)-2,3-dihydro-1H-2-benzazepine-4-carboxylate (24b)
Under a permanent flow of N2, ester 23b (160 mg, 0.45 mmol), PdCl2(dppf) (22 mg, 5 mol%), KOAc
(104 mg, 1 mmol) and 4-methylbenzeneboronic acid (79 mg, 0.5 mmol) were suspended in dry
dimethoxyethane (10 mL). The Schlenk tube was sealed and heated to 100 °C for 12 h. After cooling
down to rt, the mixture was filtered through a short silica pad (ethyl acetate). The filtrate was
concentrated in vacuo and purified by automatic fc (Biotage®, SNAP 50 g, cyclohexane / ethyl acetate)
to give 24b. Colorless solid, mp 128 °C, yield 95 mg (58%). C23H25NO3, Mr = 363.5. 1H NMR (CDCl3):
δ [ppm] = 0.94 (d, J = 6.7 Hz, 6H, NCH2CH(CH3)2), 2.02 – 2.15 (m, 1H, NCH2CH(CH3)2), 2.41 (s, 3H,
CH3), 3.46 (d, J = 7.6 Hz, 2H, NCH2CH(CH3)2), 3.89 (s, 3H, CO2CH3), 4.02 (s, 2H, 3-CH2), 7.26 – 7.30
(m, 2H, 3-CHtolyl, 5-CHtolyl), 7.47 – 7.61 (m, 3H, 2-CHtolyl, 6-CHtolyl, 6-CH), 7.71 (dd, J = 8.2/1.8 Hz,
1H, 8-CH), 7.88 (s, 1H, 5-CH), 8.15 (d, J = 8.2 Hz, 1H, 9-CH). 13C NMR (CDCl3): δ [ppm] = 20.2 (2C,
NCH2CH(CH3)2), 21.3 (1C, CH3), 27.8 (1C, NCH2CH(CH3)2), 44.5 (1C, C-3), 52.6 (1C, CO2CH3), 56.4
(1C, NCH2CH(CH3)2), 127.1 (2C, C-2tolyl, C-6tolyl), 128.1 (1C, C-8), 128.4 (1C, C-6), 129.9 (2C, C-3tolyl
,
C-5tolyl), 132.4 (1C, C-9), 133.6 (1C, C-9a), 135.1 (1C, C-5a), 136.6 (1C, C-4tolyl), 138.3 (1C, C-1tolyl),
141.9 (1C, C-5), 143.3 (1C, C-7), 166.1 (1C, CO2CH3), 168.0 (1C, C-1). IR (neat): ν [cm-1] = 2937 (C-
Haliph.), 1727 (C=Oamide), 1597 (C=C).

ACCEPTED MANUSCRIPT
26
Mixture of 24a and 24b: As described above, a mixture of the regioisomers 23a and 23b (120 mg, 0.34
mmol) was reacted with 4-methylbenzeneboronic acid (51 mg, 0.37 mmol). Pale yellow oil, yield 74 mg
(60%). Ratio 24a:24b = 1:1.
4.3.11. 2-Isobutyl-N-{4-[N-methyl-N-(tetrahydro-2H-pyran-4-yl)aminomethyl]phenyl}-1-oxo-8-(p-
tolyl)-2,3-dihydro-1H-2-benzazepine-4-carboxamide (26a)
The ester 24a (90 mg, 0.25 mmol) was dissolved in H3COH (10 mL) and 5 M NaOH (10 mL) was
added. The mixture was heated to reflux for 30 min. After cooling down to 0 °C, the mixture was
acidified with conc. HCl to give a precipitate. The aqueous layer was extracted with ethyl acetate (3 x
25 mL), the combined organic layers were dried (Na2SO4), added to the precipitate and concentrated in
vacuo to give the acid 25a. Colorless solid, yield 87 mg (97%). C22H23NO3, Mr = 349.4. Amine 13 (64
mg, 0.25 mmol, 1 equiv.) was added to a vigorously stirred mixture of acid 25a (87 mg, 0.25 mmol, 1
equiv.), trimethylamine (51 mg, 0.5 mmol, 2 equiv.) and HATU (105 mg, 0.28 mmol, 1.1 equiv.) in abs.
THF (10 mL). The mixture was stirred overnight at rt. Then the mixture was concentrated in vacuo. Sat.
NaHCO3-solution (20 mL) was added to the residue and the mixture was extracted with CH2Cl2 (3 x 20
mL). The combined organic layers were concentrated in vacuo to give a yellow oil, which was first
purified by automatic fc (Biotage®, SNAP Cartridge KP-C18-HS 30g, water/acetonitrile) to give 26a.
Pale yellow solid, yield 54 mg (39%). Exact MS (APCI): m/z = 552.3236 (calcd. 552.3221 for
1
C35H41N3O3 [MH+]). H NMR (CDCl3): δ [ppm] = 0.86 (d, J = 6.6 Hz, 6H, NCH2CH(CH3)2), 1.70 –
1.84 (m, 2H, 3-CH2pyran, 5-CH2pyran), 1.91 (d, J = 11.6 Hz, 2H, 3-CH2pyran, 5-CH2pyran), 1.95 – 2.07 (m,
1H, NCH2CH(CH3)2), 2.36 (s, 3H, CH3tolyl), 2.40 (s, 3H, NCH3), 3.09 (m, 1H, 4-CHpyran), 3.31 (m, 2H,
2-CH2pyran, 6-CH2pyran) 3.35 (d, 2H, J = 7.6 Hz, NCH2CH(CH3)2), 3.90 (s, 2H, 3-CH2), 3.95 (s, 2H,
NCH2), 4.03 (dd, J = 11.2/4.1 Hz, 2H, 2-CH2pyran, 6-CH2pyran), 7.13 (s, 1H, 5-CH), 7.16 (d, J = 8.1 Hz,
2H, 3-CHtolyl, 5-CHtolyl), 7.17 – 7.20 (m, 1H, 6-CH), 7.35 (d, J = 6.2 Hz, 2H, 2-CHtolyl, 6-CHtoly), 7.40 (d,

ACCEPTED MANUSCRIPT
27
J = 8.3 Hz, 2H, 3-CHphenyl, 5-CHphenyl), 7.62 (dd, J = 8.2/1.8 Hz, 1H, 7-CH), 7.82 (d, J = 8.2 Hz, 2H, 2-
CHphenyl, 6-CHphenyl), 8.08 (s, 1H, 9-CH), 9.62 (s, 1H, NH). 13C NMR (CDCl3): δ [ppm] = 20.2 (2C,
NCH2CH(CH3)2), 21.3 (1C, CH3tolyl), 27.7 (1C, NCH2CH(CH3)2), 27.9 (2C, C-3pyran, C-5pyran), 35.9 (1C,
NCH3), 44.6 (1C, PhCH2N), 56.23 (1C NCH2CH(CH3)2), 56.5 (1C, C-3), 59.5 (1C, C-4pyran), 67.0 (2C,
C-2pyran, C-6pyran), 120.6 (2C, C-2phenyl, C-6phenyl), 126.9 (2C, C-2tolyl, C-6tolyl), 127.0 (1C, C-7), 127.1
(1C, C-5), 127.2 (1C, C-5a), 127.4 (1C, C-6), 129.2 (1C, C-4phenyl), 129.7 (1C. C-1tolyl), 129.8 (2C, C-
3tolyl, C-5tolyl), 130.8 (2C, C-3phenyl, C-5phenyl), 131.8 (1C, C-9), 134.2 (1C, C-8), 138.3 (1C, C-4tolyl),
139.2 (1C, C-1phenyl), 141.4 (1C, C-4), 143.0 (1C, C-9a), 165.1 (1C, CONH), 168.5 (1C, C-1). IR (neat):
ν [cm-1] = 2937 (C-Haliph.), 1727 (C=Oamide), 1600 (C=C). HPLC (method 1): tR = 21.51 min, purity
98.3%.
4.3.12. 2-Isobutyl-N-{4-[N-methyl-N-(tetrahydro-2H-pyran-4-yl)aminomethyl]phenyl}-1-oxo-7-(p-
tolyl)-2,3-dihydro-1H-2-benzazepine-4-carboxamide (26b)
The ester 24b (82 mg, 0.23 mmol) was dissolved in H3COH (10 mL) and 5 M NaOH (10 mL) was
added. The mixture was heated to reflux for 30 min. After cooling down to 0 °C, the mixture was
acidified with conc. HCl to give a precipitate. The aqueous layer was extracted with EtOAc (3 x 25 mL),
the combined organic layers were dried (Na2SO4), added to the precipitate and concentrated in vacuo to
give the acid 25b. Colorless solid, yield 79 mg (97%). C22H23NO3 Mr = 349.4 g/mol. Amine 13 (58 mg,
0.23 mmol) was added to a vigorously stirred mixture of acid 25b (79 mg, 0.23 mmol), triethylamine
(46 mg, 0.45 mmol) and HATU (95 mg, 0.25 mmol) in THF (10 mL). The mixture was stirred overnight
at rt. Then the mixture was concentrated in vacuo. Saturated NaHCO3 solution (20 mL) was added to the
residue and the mixture was extracted with CH2Cl2 (3 x 20 mL). The combined organic layers were
concentrated in vacuo to give a yellow oil, which was purified by automatic fc (Biotage®, SNAP KP-
C18-HS 30 g, water/acetonitrile) to give 26b. Pale yellow solid, yield 42 mg (34%). C35H41N3O3,

ACCEPTED MANUSCRIPT
28
1
Mr = 551.7. Exact MS (APCI): m/z = 552.3236 (calcd. 552.3221 for C35H41N3O3 [MH+]). H NMR
(CDCl3): δ [ppm] = 0.88 (d, J = 6.7 Hz, 6H, NCH2CH(CH3)2), 1.72 – 1.79 (m, 2H, 3-CH2pyran, 5-
CH2pyran), 1.86-1.92 (d, J = 11.6 Hz, 2H, 3-CH2pyran, 5-CH2pyran), 2.03 (non, J = 6.9 Hz, 1H,
NCH2CH(CH3)2), 2.36 (s, 3H, NCH3), 2.40 (s, 3H, CH3tolyl), 2.89 – 3.02 (m, 1H, 4-CHpyran), 3.30 – 3.37
(m, 2H, 2-CH2pyran, 6-CH2pyran), 3.40 (d, J = 7.6 Hz, 2H, NCH2CH(CH3)2), 3.81 (s, 2H, NCH2), 3.99 (s,
2H, 3-CH2), 4.04 (dd, J = 11.3/3.8 Hz, 2H, 2-CH2pyran, 6-CH2pyran), 7.18 (d, J = 7.9 Hz, 2H, 3-CHtolyl, 5-
CHtolyl), 7.25 (m, 1H, 6-CH), 7.38 (m, 3H, 5-CH, 2-CHphenyl, 6-CHphenyl), 7.42 (d, J = 8.1 Hz, 2H, 3-
CHphenyl, 5-CHphenyl), 7.64 (dd, J = 8.2/1.8 Hz, 1H, 8-CH), 7.78 (d, J = 8.3 Hz, 2H, 2-CHphenyl, 6-
13
CHphenyl), 8.10 (d, J = 8.2 Hz, 1H, 9-CH), 9.23 (s, 1H, NH). C NMR (CDCl3): δ [ppm] = 20.2 (2C,
NCH2CH(CH3)2), 21.3 (1C, CH3tolyl), 27.7 (1C, NCH2CH(CH3)2), 28.3 (2C, C-3pyran, C-5pyran), 36.5 (1C,
NCH3), 44.7 (1C, C-3), 56.2 (1C NCH2CH(CH3)2), 56.9 (1C, PhCH2N), 59.7 (1C, C-4pyran), 67.3 (2C, C-
2pyran, C-6pyran), 120.5 (2C, C-2phenyl, C-6phenyl), 127.0 (2C, C-2tolyl, C-6tolyl), 127.3 (1C, C-6), 127.5 (1C,
C-8), 129.8 (2C, C-3tolyl, C-5tolyl), 130.5 (2C, C-3phenyl, C-5phenyl), 131.9 (1C, C-9), 133.8 (1C, C-5a),
134.4 (1C, C-9a), 135.6 (1C, C-5), 136.2 (1C. C-1tolyl), 137.6 (1C, C-1phenyl), 138.3 (1C, C-4tolyl), 138.6
(1C, C-4phenyl), 143.1 (1C, C-7), 165.0 (1C, CONH), 168.4 (1C, C-1). IR (neat): ν [cm-1] = 2937 (C-
Haliph.), 1728 (C=Oamide), 1600 (C=C). HPLC (method 1): tR = 23.08 min, purity 97.1%.
Separation of regioisomeric 26a and 26b: As described above, a mixture of the regioisomers 24a and
24b (74 mg, 0.2 mmol) was reacted with 5 M NaOH (5 mL) and the resulting mixture of acids 25a and
25b was subsequently coupled with primary amine 13 (51 mg, 0.2 mmol) and HATU (83 mg, 0.22
mmol). Pale yellow oil, yield 51 mg (46%). The 1:1-mixture of regioisomers 26a and 26b was separated
by preparative HPLC (method 2, acetonitrile : H2O = 70:30, 60 min per run). 26a: Colorless solid, yield
12 mg (24%). 26b: Colorless solid, yield 16 mg (31%).

ACCEPTED MANUSCRIPT
29
4.3.13. Methyl 2-isobutyl-8-nitro-1-oxo-2,3-dihydro-1H-2-benzazepine-4-carboxylate (27a) and
Methyl 2-isobutyl-6-nitro-1-oxo-2,3-dihydro-1H-2-benzazepine-4-carboxylate (27c)
Concentrated H2SO4 (1.04 mL) was added slowly, with ice-water cooling and stirring, to 100% HNO3
(1.04 mL). 11 (280 mg, 1.02 mmol, 1 equiv.) was dissolved in nitromethane (0.5 mL) and cooled to
0 °C. After nitrating acid was added slowly at this temperature, the solution was warmed to rt and stirred
for 2 h. Then ice-water was poured into the reaction mixture, neutralized with 3 M NaOH (10 mL) and
extracted with CH2Cl2 (2 x 15 mL) and ethyl acetate (2 x 15 mL). The combined organic layers were
dried (Na2SO4) and concentrated in vacuo. The residue was purified by fc (Ø = 3 cm, h = 17 cm,
cyclohexane / ethyl acetate = 7 : 2, V = 20 mL, Rf = 0.02 (cyclohexane / ethyl acetate = 7 : 2)) to give a
mixture of regioisomers 27a and 27c. Pale yellow oil, yield 273 mg (83%). C16H18N2O5,
Mr = 318.3. Ratio of 27a:27c = 7:3. Exact mass (ESI): m/z = 341.1109 (calcd. 341.1108 for
C16H18N2NaO5 [MNa+]). IR (neat): ν [cm-1] = 2959 (C-Halkyl), 1713 (C=O), 1636 (NC=O), 1524 (N=O),
1346 (NO2 arom.). HPLC (method 1): tR = 20.43 min, purity 97.7%. The two regioisomers were separated
by fc (Ø = 2.5 cm, h = 24 cm, CH2Cl2 : ethyl acetate = 95 : 5, V = 20 mL) to give 27a and 27c.
27a (Rf = 0.38, CH2Cl2 : ethyl acetate = 95 : 5): Pale yellow solid, mp 109 °C, yield 178 mg (54%).
C16H18N2O5, Mr = 318.3. Exact mass (ESI): m/z = 341.1106 (calcd. 341.1108 for C16H18N2NaO5
1
[MNa+]). H NMR (CDCl3): δ [ppm] = 0.94 (d, J = 6.7 Hz, 6H, NCH2CH(CH3)2), 2.14 – 2.21 (m, 1H,
NCH2CH(CH3)2), 3.45 (d, J = 7.6 Hz, 2H, NCH2CH(CH3)2), 3.91 (s, 3H, CO2CH3), 4.02 (s, 2H, 3-CH2),
7.53 (d, J = 8.5 Hz, 1H, 6-CH), 7.84 (s, 1H, 5-CH), 8.30 (dd, J = 8.5/2.4 Hz, 1H, 7-CH), 8.92 (d, J = 2.0
13
Hz, 1H, 9-CH). C NMR (CDCl3): δ [ppm] = 20.1 (2C, NCH2CH(CH3)2), 27.7 (1C, NCH2CH(CH3)2),
44.2 (1C, C-3), 53.0 (1C, CO2CH3), 56.6 (1C, NCH2CH(CH3)2), 124.8 (1C, C-7), 127.3 (1C, C-9), 130.9
(1C, C-6), 136.0 (1C, C-4), 138.2 (1C, C-9a), 138.4 (1C, C-5a), 139.2 (1C, C-5), 148.3 (1C, C-8), 165.4
(1C, CO2CH3), 166.2 (1C, C-1). FT-IR (neat): ν [cm-1] = 2963 (C-Halkyl), 1709 (C=O), 1632 (NC=O),
1520 (N=O), 1354 (NO2 arom.). HPLC (method 1): tR = 20.81 min, purity 96.5%.